Last reviewed · How we verify

NCT07274826

Diagnostic Creteria of Acid Sphingomyelinase Deficiency (ASMD)

Active, enrolled Last updated 10 December 2025
What this trial tests

trial in Acid Sphingomyelinase Deficiency (ASMD) in 7 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
20 November 2025
Primary endpoint
10 August 2026
10 September 2026

Quick facts

Lead sponsorSohag University
StatusActive, enrolled
Study typeOBSERVATIONAL
Enrollment7
Start date20 November 2025
Primary completion10 August 2026
Estimated completion10 September 2026
Sites1 location across Egypt

Conditions studied

Sponsor

Sohag University

Who can join

Eligibility, any sex, with Acid Sphingomyelinase Deficiency (ASMD). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Acid sphingomyelinase Deficiency known as Neiman \_PICK disease is a group of rare genetic diseases. This study includes analysis of clinical manifestations in patients with ASMD and investigations done for diagnosis of these patients

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Sohag University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07274826.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing